GERN
Geron·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GERN
Geron Corporation
A late-stage clinical biopharmaceutical company that develops telomerase-targeted and peptide-drug conjugate therapies for cancers
919 East Hillsdale Boulevard
, Suite 250
, Foster City
, CA 94404
--
Geron Corporation was incorporated in Delaware on November 28, 1990. The company is a biopharmaceutical company that develops first-in-class treatments for cancer treatment. Imetelstat is a novel, first-in-class telomerase inhibitor and a candidate for the company's clinically developing product. Telomerase enables tumor cells to maintain telomere length, which provides the ability for infinite cellular replication. Imetelstat is a potent specific telomerase inhibitor. On the basis of clinical data obtained at the end of 2012, Imetelstat may be developed for the treatment of one or more myeloid malignancies of the hematopoietic system, such as myelofibrosis, or MF, myelodysplastic syndrome, or acute myeloid leukemia. Using the company's proprietary nucleic acid chemistry, Imetelstat is designed to modify oligonucleotides, the active site of telomerase has a high affinity, thereby directly inhibiting telomerase activity. The company's development of Imetelstat and US commercial patent coverage extends to 2025.
Earnings Call
Q2/2025
Estimate EPS-0.03
Actual EPS-0.02
Estimate Revenue47.30M
Actual Revenue49.00M
Geron Corporation's Q2 2025: Unraveling Contradictions in Patient Demand, Physician Intent, and Revenue Strategies
Aug 06,2025 03:11
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
GERN has released its 2025 Q3 earnings. EPS was reported at -0.03, versus the expected -0.04, beating expectations. The chart below visualizes how GERN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GERN has released its 2025 Q3 earnings report, with revenue of 47.23M, reflecting a YoY change of 67.05%, and net profit of -18.43M, showing a YoY change of 30.32%. The Sankey diagram below clearly presents GERN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
